PNC-27
Also known as: p53-MDM2 peptide, PNC27
PNC-27 (also called p53-MDM2 peptide or PNC27) is an experimental anticancer peptide in the Membrane-lytic research peptide class. PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence.
For research use only.
Key Facts
- CAS
- 1159861-00-3
- Molecular Weight (MW)
- 4032 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Research only
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Membrane HDM-2 (claimed)
Research summary
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
Peptide Library's PNC-27 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established — preclinical only
- Frequency
- —
- Cycle
- —
- Administration Route
- Research only
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. PNC-27 is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C188H293N53O44S |
|---|---|
| Molecular weight | 4032 g/mol |
| CAS number | 1159861-00-3 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 16201774 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence. The proposed mechanism is that it binds HDM-2 present in the plasma membrane of cancer cells — reported to be expressed there in transformed but not normal cells — and forms transmembrane pores, causing rapid necrotic lysis rather than apoptosis. Selectivity in this model derives entirely from the claimed differential membrane localisation of HDM-2. The evidence is preclinical and comes largely from a small number of groups, replication is limited, and there are no clinical trials. Products sold under this name are research chemicals, not oncology drugs.
Origin
Synthetic p53-derived peptide.
Targets
Studies
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
- Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Regulatory & research status
PNC-27 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Unknown; membrane-lytic peptides can be cytotoxic
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PNC-27: frequently asked questions
What is PNC-27?
Experimental peptide containing a p53 motif designed to lyse cancer-cell membranes in preclinical papers. Not FDA-approved; not a cancer treatment.
How does PNC-27 work?
PNC-27 is a synthetic peptide joining a p53 -derived HDM-2 binding region to a membrane-penetrating leader sequence. The proposed mechanism is that it binds HDM-2 present in the plasma membrane of cancer cells — reported to be expressed there in transformed but not normal cells — and forms transmembrane pores, causing rapid necrotic lysis rather than apoptosis.
Is PNC-27 FDA approved?
No. PNC-27 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to PNC-27?
Compounds most often compared with PNC-27 include Bonomarlot, Bronchogen, Chonluten and Glutathione. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells — Ann Clin Lab Sci, 2025External reference
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption — Ann Clin Lab Sci, 2024External reference
- Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study — Iran J Basic Med Sci, 2022External reference
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis — Biomedicines, 2022External reference
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells — Anticancer Res, 2020External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 2
This PNC-27 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PNC-27 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →